The two companies will integrate techniques temperature-controlled logistics to enhance cell and gene therapy distribution. Alex Guite, VP of strategy and services at world courier, told us, “Cell and gene therapies are changing the world of medicine and demonstrating transformative results in clinical trials and real world application.”
Japan is growing in its cell and gene therapy clinical and commercial activity. The projected global gene and cell market size in Japan is expected to grow to more than $50bn (€43bn) by 2025.
However, Guite further explained, that logistics for transporting cell and gene therapies is not a simple process: “executing the logistics of cell and gene therapies, in particular, is a challenge like no other as the products involve living cells with an extremely limited shelf life.”
The collaboration will offer Japan-based customers the ability to use World Courier’s global cold chain network for cell and gene therapy supply chains, and Suzuken’s access to the Japanese market.
World Courier’s logistics platform includes a fully good practice (GXP) compliant network of more than 140 offices, with controlled deliveries performed between 18°C and -190°C.
Guite told us, “It’s critical that stakeholders in this market have access to the temperature control solutions needed to ensure product quality and integrity throughout the delivery. After all, if you cannot deliver the therapy to the patient, its efficacy is irrelevant, as the patient receives no benefit.”